Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists.
Dermatology
Generalized pustular psoriasis
Psoriasis
Survey
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
16
12
2020
accepted:
23
01
2021
pubmed:
28
2
2021
medline:
28
2
2021
entrez:
27
2
2021
Statut:
ppublish
Résumé
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening systemic and chronic autoinflammatory disease characterized by sterile, neutrophilic pustules. The standard of care for GPP varies by region, with limited information and experience of flares and their treatment. Our aim was to establish current unmet needs in GPP by better understanding the natural history of GPP, examining how dermatologists diagnose GPP and GPP flares, and establishing the range and adequacy of GPP treatment options currently prescribed by dermatologists. Eligible dermatologists (N = 29) completed a 28-question structured survey, covering ten themes, ranging from GPP diagnostic criteria to GPP symptoms and treatment. All dermatologists stated that pustules were necessary to diagnose a GPP flare. The most frequently reported triggering factors for GPP were steroid withdrawal (64%), infection (58%), and stress (50%). Most dermatologists indicated that available treatment options for GPP flares were adequate "most" (79%) or "all" (14%) of the time. Despite this reported adequacy, 38% of dermatologists reported that it was at least "somewhat common" for a flare to require hospitalization. Furthermore, 72% of dermatologists indicated that treatments were too slow to control flares, and 66% indicated that treatments did not adequately prevent new flares at least "sometimes". This survey suggests that there are key features of GPP flares, and could initiate discussion around forming consensus guidelines for diagnosis and management. While the results suggest that moderately effective therapies may exist, the need for GPP-specific treatments remains.
Identifiants
pubmed: 33638115
doi: 10.1007/s13555-021-00493-0
pii: 10.1007/s13555-021-00493-0
pmc: PMC8018987
doi:
Types de publication
Journal Article
Langues
eng
Pagination
529-541Références
Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43-54.
doi: 10.1007/s00403-002-0371-6
Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–44.
Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42.
Guerreiro de Moura CA, de Assis LH, Góes P, et al. A case of acute generalized pustular psoriasis of von Zumbusch triggered by hypocalcemia. Case Rep Dermatol. 2015;7:345–51.
doi: 10.1159/000442380
Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–9.
doi: 10.1111/jdv.14386
Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor. Malaysia Int J Dermatol. 2014;53:676–84.
doi: 10.1111/ijd.12070
Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br J Dermatol. 1971;85:407–11.
doi: 10.1111/j.1365-2133.1971.tb14044.x
Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127:1339–45.
doi: 10.1001/archderm.1991.01680080075005
Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16:669–73.
pubmed: 17229609
Zhou LL, Georgakopoulos JR, Ighani A, Yeung J. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22:591–601.
doi: 10.1177/1203475418773358
Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–88.
doi: 10.1016/j.jaad.2011.01.032
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–19.
doi: 10.1080/1744666X.2019.1648209
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235–70.
doi: 10.1111/1346-8138.14523
Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018;178:614–8.
doi: 10.1111/bjd.16232
Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20.
doi: 10.1016/j.jaci.2016.08.056
Georgala S, Rigopoulos D, Aroni K, Stratigos J. Generalised pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol. 1994;33:515–6.
doi: 10.1111/j.1365-4362.1994.tb02871.x
Georgala S, Koumantaki E, Rallis E, Papadavid E. Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy. Br J Dermatol. 2000;142:1057–8.
doi: 10.1046/j.1365-2133.2000.03503.x